Loading...
•
Sep 30, 2021
Allakos Q3 2021 Earnings Report
Allakos reported financial results for the third quarter ended September 30, 2021.
Key Takeaways
Allakos reported a net loss of $62.7 million in the third quarter of 2021, compared to a net loss of $42.1 million in the same period in 2020. The company ended the quarter with $505.6 million in cash, cash equivalents and marketable securities.
Presented data at ACG 2021 showing high prevalence rates of EG/EoD with systemic evaluation.
Topline data from a Phase 3 study of lirentelimab in patients with EG/EoD expected in Q4 2021 or early Q1 2022.
Topline data from a Phase 2/3 study of lirentelimab in patients with EoE expected in Q4 2021 or early Q1 2022.
Initiation of a Phase 2/3 study of subcutaneous lirentelimab in patients with EG and/or EoD expected in Q4 2021.
Forward Guidance
This press release contains forward-looking statements regarding Allakos' progress and business plans, the expected timing of anticipated study results and plans relating to its future clinical trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...